News coverage about Audentes Therapeutics (NASDAQ:BOLD) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Audentes Therapeutics earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 47.3125898168137 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Audentes Therapeutics (BOLD) traded up $0.49 on Friday, reaching $25.29. 72,800 shares of the company’s stock were exchanged, compared to its average volume of 140,735. Audentes Therapeutics has a 1 year low of $13.90 and a 1 year high of $33.43.
Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($0.10). sell-side analysts anticipate that Audentes Therapeutics will post -3.53 earnings per share for the current fiscal year.
Several research firms recently issued reports on BOLD. Zacks Investment Research downgraded shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 8th. Evercore ISI began coverage on shares of Audentes Therapeutics in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 price target for the company. ValuEngine raised shares of Audentes Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 20th. William Blair began coverage on shares of Audentes Therapeutics in a research report on Tuesday, October 17th. They issued an “outperform” rating and a $35.00 price target for the company. Finally, Raymond James Financial, Inc. began coverage on shares of Audentes Therapeutics in a research report on Thursday, October 12th. They issued a “market perform” rating for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $25.71.
COPYRIGHT VIOLATION WARNING: “Audentes Therapeutics (BOLD) Earning Somewhat Positive Media Coverage, Report Shows” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://stocknewstimes.com/2017/11/11/audentes-therapeutics-bold-earning-somewhat-positive-media-coverage-report-shows.html.
In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 25,000 shares of Audentes Therapeutics stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $27.92, for a total transaction of $698,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Suyash Prasad sold 8,000 shares of Audentes Therapeutics stock in a transaction on Friday, September 1st. The stock was sold at an average price of $21.44, for a total transaction of $171,520.00. Following the transaction, the vice president now directly owns 8,000 shares in the company, valued at $171,520. The disclosure for this sale can be found here. Insiders have sold a total of 766,500 shares of company stock worth $21,443,730 over the last ninety days. Insiders own 47.30% of the company’s stock.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.